Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington\u27s disease by Vazey, Elena M et al.
University of Wollongong
Research Online
Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health
2010
Comparison of transplant efficiency between
spontaneously derived and noggin-primed human
embryonic stem cell neural precursors in the




University of Melbourne, mdottori@uow.edu.au
Pegah Jamshidi




University of Southern California
See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Vazey, E. M., Dottori, M., Jamshidi, P., Tomas, D., Pera, M. F., Horne, M. & Connor, B. (2010). Comparison of transplant efficiency
between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of
Huntington's disease. Cell Transplantation, 19 (8), 1055-1062.
Comparison of transplant efficiency between spontaneously derived and
noggin-primed human embryonic stem cell neural precursors in the
quinolinic acid rat model of Huntington's disease
Abstract
Human neural precursors (hNP) derived from embryonic stem cells (hESC) may provide a viable cellular
source for transplantation therapy for Huntington's disease (HD). However, developing effective
transplantation therapy for the central nervous system (CNS) using hESC relies on optimizing the in vitro
production of hNP to control appropriate in vivo posttransplantation neuronal differentiation. The current
study provides the first direct in vivo comparison of the transplant efficiency and posttransplantation
characteristics of spontaneously derived and noggin-primed hNP following transplantation into the
quinolinic acid (QA) rat model of HD. We show that spontaneously derived and noggin-primed hNP both
survived robustly up to 8 weeks after transplantation into the QA-lesioned striatum of the adult rat.
Transplanted hNP underwent extensive migration and large-scale differentiation towards a predominantly
neuronal fate by 8 weeks post-transplantation. Furthermore, in vitro noggin priming of hNP specifically
increased the extent of neuronal differentiation at both 4 and 8 weeks posttransplantation when compared to
spontaneously derived hNP grafts. The results of this study suggest that in vit ro noggin priming provides an
effective mechanism by which to enhance hNP transplant efficiency for the treatment of HD.
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Brief Communication
Comparison of Transplant Efficiency Between Spontaneously
Derived and Noggin-Primed Human Embryonic Stem Cell Neural
Precursors in the Quinolinic Acid Rat Model of Huntington’s Disease
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Martin F. Pera,¶ Malcolm Horne,‡§ and Bronwen Connor*
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Human neural precursors (hNP) derived from embryonic stem cells (hESC) may provide a viable cellular
source for transplantation therapy for Huntington’s disease (HD). However, developing effective transplanta-
tion therapy for the central nervous system (CNS) using hESC relies on optimizing the in vitro production
of hNP to control appropriate in vivo posttransplantation neuronal differentiation. The current study provides
the first direct in vivo comparison of the transplant efficiency and posttransplantation characteristics of
spontaneously derived and noggin-primed hNP following transplantation into the quinolinic acid (QA) rat
model of HD. We show that spontaneously derived and noggin-primed hNP both survived robustly up to 8
weeks after transplantation into the QA-lesioned striatum of the adult rat. Transplanted hNP underwent
extensive migration and large-scale differentiation towards a predominantly neuronal fate by 8 weeks post-
transplantation. Furthermore, in vitro noggin priming of hNP specifically increased the extent of neuronal
differentiation at both 4 and 8 weeks posttransplantation when compared to spontaneously derived hNP
grafts. The results of this study suggest that in vitro noggin priming provides an effective mechanism by
which to enhance hNP transplant efficiency for the treatment of HD.
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INTRODUCTION proof-of-principle evidence of neuroanatomical integra-
tion that alleviates clinically relevant motor and cogni-
tive deficits (5,6,9–11,14,20,23,24,28,29,36). As a result,Huntington’s disease (HD) is an autosomal dominant
genetic neurodegenerative disorder (19) characterized by primary fetal tissue transplantation for HD is currently
undergoing clinical evaluation (2,3,12,13,15–18,22,31–33).involuntary movements, cognitive deficits, and behav-
ioral changes due to the progressive and selective degen- However, ethical and technical issues associated with
the use of primary fetal tissue for cell transplantationeration of striatal GABAergic medium spiny projection
neurons. HD is a good candidate for cell transplantation therapy have prompted studies to evaluate the potential
of alternative renewable cell sources for transplantationtherapy because there is no effective treatment and there
is the potential for early intervention. Primary fetal cells therapy. Recent studies have identified the therapeutic
value of various types of stem/progenitor cell transplantsgrafted into animal models of HD have demonstrated
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for HD (29,39,40). In particular, human embryonic stem undertaken 1 week after 50 nM QA lesioning (at coordi-
nates AP +0.5 mm, ML +2.7 mm, DV −5.0 mm).cells (hESC) have the potential to provide a stable and
unlimited cell source for transplantation therapy (35). Cyclosporine (10 mg/kg, SC) was administered three
times weekly for the duration of the experiment begin-The feasibility of transplanting hESC into the central
nervous system (CNS) relies on the in vitro production ning 48 h prior to transplantation. Animals were trans-
cardially perfused with 4% paraformaldehyde after ter-of neural precursors (hNP). There are several methods
for deriving hNP from hESC (1,21,27,30,37) but the minal anesthesia with sodium pentobarbitone (120 mg/
kg, IP) either 4 (n = 8) or 8 (n = 9) weeks after trans-transplant efficiency and posttransplantation characteris-
tics of hNP derived with these methods have not been plantation, brains were then postfixed in 4% paraformal-
dehyde overnight before further processing.compared under the same in vivo conditions. One of the
original methods for deriving NP from hESC relied on Brains were cryoprotected in 30% sucrose and sec-
tioned on a Microm HM450 sliding microtome set at 40the spontaneous generation of rosette-like structures in
differentiated colonies of hESC (30). Pera and col- µm. Eight series of sections (320 µm between consecu-
tive sections within a series) were collected and storedleagues (26) advanced this technique by the develop-
ment of an efficient and controlled serum-free method in cryoprotective solution at −20°C. For immunofluores-
cence, sections were incubated with the appropriate pri-for deriving hNP-rich cultures from hESC by priming
cultures through the addition of the bone morphogenic mary antibodies. Antibodies were used at the following
concentrations: mouse anti-MAP2 1:1000 (Millipore,protein antagonist noggin. Noggin-induced hNP can be
maintained as free-floating neurospheres that differenti- USA), mouse anti-Pax6-s 1:20 (Developmental Studies
Hybridoma Bank, IA, USA) mouse anti-NeuN 1:500ate in vitro into astrocytes, oligodendrocytes, and elec-
trophysiologically mature neurons (21,26). In the current (Millipore), rabbit anti-GFAP 1:500 (DAKO, Sweden),
rabbit anti-DARPP-32 1:500 (Millipore), rabbit anti-study we use both spontaneous derivation in neural me-
dium (30) and noggin-primed derivation (21) to induce GAD67 1:1000 (Millipore), mouse anti-Ki67 1:200
(MIB-1 clone, DAKO), and mouse anti-Oct3/4 1:40hNP from hESC. Transplant efficiency and posttrans-
plantation characteristics of hNP derived from each (Santa Cruz). Secondary goat anti-rabbit and goat anti-
mouse Alexa FluorTM 594 antibodies (1:200, Invitrogen)method were directly compared in vivo using the quino-
linic acid (QA) lesion model of HD. were used. Fluorescently labeled sections were imaged
using a confocal laser-scanning microscope (Leica TCS
MATERIALS AND METHODS SP2) equipped with UV, argon, argon/krypton and he-
lium/neon lasers (Biomedical Imaging Resource Unit,The GFP-expressing hESC line ENVY (7) was used
for posttransplantation identification of hNP. This line University of Auckland).
GFP and the fluorescent labels were imaged seriallyexpresses GFP at sustained, high levels throughout the
entire cell in all differentiated progeny. ENVY hNPs to eliminate detection of bleed through and other arti-
factual fluorescence. To confirm colocalization confocalwere derived either by noggin treatment (500 ng/ml) of
hESC (8) or by spontaneous hESC differentiation (30). images were captured in a Z-series with an interslice gap
of 0.3 µm. Graft volume was quantified from a set ofIn both conditions, rosette structures were mechanically
harvested and cultured in suspension in neural medium serial coronal sections (distance 320 µm) from each ani-
mal. Graft core GFP expression was analyzed usingsupplemented with growth factors to allow neurospheres
formation as previously described (30). hESC-derived Stereo InvestigatorTM (Microbrightfield, Williston, VT,
USA) linked to a Nikon e800 upright microscope withneurospheres were cultured for 3 weeks prior to the day
of transplantation, upon which they were collected, gen- epiflourescent capabilities. All statistical analysis was
undertaken using Graphpad Prism v4.02 (Graphpadtly dissociated using Cell Dissociation Buffer (Invitro-
gen), and suspended in neurobasal medium without growth Software Inc., CA, USA). Analysis between groups at
the same time point was undertaken using two-tailed un-factors at 37,500 cells/µl for transplantation. All experi-
ments were performed in strict compliance with the Flo- paired Student’s t-tests, whereas comparisons between
multiple groups at different time points were undertakenrey Neuroscience Institute Animal Ethics Guidelines and
conformed to international guidelines on the ethical use using two-way ANOVA analysis with Bonferroni post
hoc analysis. All results are presented as mean ± SEMof animals.
Adult male Wistar rats (250–300 g at QA lesion) re- and deemed statistically significant if p < 0.05.
ceived surgery under IP anesthesia using 0.1 ml/kg of a
RESULTS7:3 mix of ketamine (100 mg/ml) and xylazine (20 mg/
ml). Transplantation of 2 µl/site of hNPs across two Both spontaneously derived and noggin-primed ENVY
hNPs transplants produced robust dense graft cores insites in the striatum (relative to bregma: AP +0.7 mm
and ML +2.5 mm, DV −5.0 mm and −4.0 mm) was the QA-lesioned striatum that survived up to 8 weeks
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posttransplantation (Fig. 1A, B). Occasional GFP-posi- a mature phenotype. Analysis of expression of neuronal
markers MAP2 (Fig. 2A–C) and NeuN (Fig. 2D–F)tive hNPs were observed to extend up the needle tract
and into the ipsilateral cortex (boxed region in Fig. 1A). confirmed that grafted hNP were highly directed to-
wards a neuronal fate after transplantation into the le-Human nuclei staining confirmed that grafts expressing
GFP were of human origin (Fig. 1C). Grafts were pres- sioned striatum. Many GFP-positive cells coexpressed
the neuronal marker MAP2 (isoforms a, b, and c) at bothent in 7/8 recipient rats at 4 weeks posttransplantation
and 7/9 recipient rats by 8 weeks posttransplantation; 4 and 8 weeks posttransplantation (Fig. 2A, B), with
variable staining intensity. The number and proportionoverall grafts survived in 14/17 of transplanted rats. By
8 weeks posttransplantion, 1/4 of the spontaneously de- of MAP2 coexpressing cells (in both noggin-primed and
spontaneously derived transplants) increased between 4rived hNPs grafts had developed into a large hyperplasic
growth. The severely hyperplasic spontaneously derived and 8 weeks posttransplantation (p = 0.02 spontaneously
derived, p = 0.008 noggin primed) (Fig. 2C). Further-hNP graft in the 8 week cohort compressed the ventricle
walls and contained intragraft rosettes (Fig. 1D). This more, in noggin-primed hNP grafts there were more
GFP-positive cells coexpressing MAP2 than in sponta-excessive overgrowth was not seen in any of the noggin-
primed grafts, suggesting that highly proliferative cells neously derived hNP grafts at both 4 weeks (21.50 ±
1.71 noggin primed vs. 4.00 ± 1.78 cells per 375 µm2 ofremained in the neurospheres of spontaneously derived
hNP even after 3 weeks induction in neural medium. the graft core spontaneously derived; p = 0.0004) and 8
weeks (48.00 ± 6.58 noggin primed vs. 22.75 ± 5.65Within the hyperplasic growth Oct3/4-positive pluripo-
tent hESC (Fig. 1E) and a large numbers of human cells per 375 µm2 of the graft core spontaneously de-
rived; p = 0.03) posttransplantation (Fig. 2C).Ki67-positive proliferating cells (Fig. 1F) were found.
The animal with spontaneously derived hNP that formed We also observed a population of grafted hNP differ-
entiated into mature neurons. These cells were locatedsevere hyperplasia was excluded from subsequent anal-
yses. mostly at the graft/host interface and were identified by
NeuN coexpression (Fig. 2D, E). More noggin-primedEpifluorescence microscopy and the Microbrightfield
Stereo InvestigatorTM system were used to quantify the grafted hNP expressed NeuN than spontaneously de-
rived hNP at both 4 weeks (9.50 ± 1.56 noggin primedvolume of the graft core. Quantification identified that
at both 4 and 8 weeks posttransplantation, spontaneously vs 4.00 ± 1.68 spontaneously derived cells per 375 µm2
of the graft core; p = 0.05) and 8 weeks (22.00 ± 5.22derived hNP grafts were larger than noggin-primed hNP
grafts (p = 0.03 and p = 0.04, respectively, two-tailed t- noggin-primed vs. 6.67 ± 0.88 spontaneously derived
cells per 375 µm2 of the graft core; p = 0.04) posttrans-test) (Fig. 1G). We also observed a nonsignificant trend
for the volume of both types of graft to decrease with plantation (Fig. 2F). Astrocytes were also observed to
surround the edges of the ENVY hNP grafts and occa-time (Fig. 1G). After transplantation, GFP-positive cell
bodies from both spontaneously derived and noggin- sionally entered the grafts with most appearing to be
host derived. Occasionally astrocytic differentiation ofprimed grafts were found not only in the graft core at
the site of injection, but also distributed rostrocaudally grafted hNP was seen within the main body of the
ENVY hNP grafts as demonstrated by low levels ofthroughout the lesioned striatum with GFP-positive cells
migrating up to 3 mm from the injection site (Fig. 1H). GFAP coexpression at 8 weeks (3.50 ± 0.65 spontane-
ously derived and 2.50 ± 0.65 noggin primed cells perHowever, the distribution of hNP cells varied greatly
between animals and both spontaneously derived and 375 µm2 of the graft core) (Fig. 2G–I). These results
demonstrate that spontaneously derived and noggin-noggin-primed hNP were observed overall to have a
similar migratory capacity (p = 0.74, two-way ANOVA) primed hNP undergo large-scale differentiation predom-
inantly towards a neuronal fate by 8 weeks posttrans-(Fig. 1H). In addition, GFP-positive processes were
found to extend up to 3.5 mm from the injection site in plantation, with in vitro priming of hNP with noggin
specifically increasing the extent of neuronal differentia-both 4 and 8 weeks posttransplant with no difference
observed over time between transplants (p = 0.30, two- tion. The extensive neuronal differentiation of grafted
ENVY hNP prompted a search for the expression of stri-way ANOVA) (Fig. 1I).
Double fluorescent labeling and confocal microscopy atal markers that are selectively lost in animal models
of HD. However, neither DARPP-32 nor GAD67 waswas used to identify the phenotypic fate of grafted hNP.
Cells within the striatum were randomly sampled and coexpressed by grafted ENVY hNP in either group at 4
or 8 weeks after transplantation (data not shown).analyzed for coexpression of Pax-6, NeuN, MAP2, and
GFAP. At both 4 and 8 weeks posttransplantation the
DISCUSSIONneural progenitor cell marker Pax-6 was absent from all
but a few transplanted cells in some animals (data not This study has directly compared the transplant effi-
ciency and posttransplantation characteristics of hNP de-shown), indicating that most grafted hNP had developed
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Figure 1. Survival, migration, and tumor formation of transplanted ENVY hNPs in the QA-lesioned striatum. Endogenous GFP
expression in spontaneously derived (A) and noggin-primed (B) hNP grafts 8 weeks after transplantation into the QA-lesioned
striatum; boxed region in (A) denotes grafted ENVY cells in needle tract. Scale bar: 2 mm for both (A) and (B). (C) Merged
confocal image of GFP (green) and HuNu (red) coexpression confirming that GFP expression is maintained in xenotransplanted
hNPs after 8 weeks in vivo. Scale bar: 8 µm. (D) Confocal slice through hyperplasic overgrowth with characteristic rosette struc-
tures from spontaneously derived hNP graft. Scale bar: 40 µm. (E) Oct3/4 (red) and (F) Ki67 (red) expression within hyperplasic
overgrowth from a spontaneously derived hNP graft (green). Scale bar: 16 µm for both (E) and (F). (G) Graph of relative graft
core volume for noggin-primed and spontaneously derived grafts at 4 and 8 weeks posttransplantation. (H) The migration of GFP-
positive cells and (I) extent of GFP-positive processes from injection site.
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Figure 2. Neural differentiation of transplanted ENVY hNP in the QA-lesioned striatum. (A, B) Representative MAP2 expression
(red) in spontaneously derived hNP grafts (A; green) and noggin-primed hNP grafts (B; green) 8 weeks after transplantation. (C)
Graph demonstrating the number of MAP2-positive hNP cells per 375 µm2 in the graft core. (D, E) Representative NeuN expression
(red) in spontaneously derived hNP grafts (D; green) and noggin-primed hNP grafts (E; green) 8 weeks after transplantation. Graph
demonstrating the number of NeuN (F) positive hNP cells per 375 µm2 in the graft core. (G, H) Representative GFAP expression
(red) in spontaneously derived hNP grafts (G; green) and noggin-primed hNP grafts (H; green) 8 weeks after transplantation. Graph
demonstrating the number of (I) GFAP-positive hNP cells per 375 µm2 in the graft core. Bonferroni post hoc pairwise comparisons.
*p < 0.05, **p < 0.01. Scale bars: 16 µm.
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rived by two different methods. We have established in Although ENVY hNP grafted into the QA-lesioned
striatum differentiated into mature neurons relativelythe QA-lesioned rat striatum that noggin-primed hNP
have a greater capacity to survive long term and differ- early, expression of striatal-specific markers such as
DARPP-32 expression was not observed by 8 weeksentiate into neurons than spontaneously derived hNP. In
addition, hyperplasic growths and aberrant differentia- posttransplantation. In contrast, we have previously
demonstrated that 8 weeks is sufficient for DARPP-32-tion was not observed to accompany grafting of noggin-
primed hNP even up to 8 weeks posttransplantation, positive neurons to develop following the transplanta-
tion of adult rodent NP into the QA-lesioned striatumwhereas grafts of spontaneously derived hNP had the
capacity to form tumors. This suggests that noggin prim- (39). This suggests either that region-specific neuronal
phenotypes are slower to develop from xenotransplanteding of hESC may provide an important safety advan-
tages for hNP transplantation. We suspect this is because hNP than in allogenic transplanted progenitors, or that
NP from embryonic stem cells are slower than thosenoggin priming induces hNP further toward a neuronal
fate while in vitro and still within neurosphere aggre- from adult sources to develop a mature phenotypic iden-
tity. Future transplantation studies using embryonic and/gates. At the time of transplantation, spontaneously de-
rived hNP likely comprise a more heterogeneous cell or human stem cell sources should be sure to contain an
extended period of investigation in order to confirm thepopulation, including residual pluripotent cells, increas-
ing the potential for tumor formation. Hyperplasic over- generation of region-specific striatal phenotypes.
In this study we have made the first direct compari-growth of hESC derived neural grafts and teratoma for-
mation are commonly encountered; indeed, other studies son of the transplant efficiency and differentiation po-
tential of spontaneously derived and noggin-primedhave reported either high rates of tumor formation or
reduced rates of survival with the transplantation of ex- hESC-derived NP in the QA lesion rat model of HD. By
establishing the efficiency and safety of noggin-primedtensively differentiated hESC-derived dopaminergic neu-
rons in animal models of Parkinson’s disease (4,25, hNPs against traditional neuronal direction paradigms in
vivo in a lesioned environment, we are able to identify34,38).
A small number of studies have recently been pub- the value of larger future investigations using noggin
primed hNPs. The safety and efficiency of noggin-lished on hESC-derived stromal cell-induced hNP trans-
plants in animal models of HD (1,37). Song and col- primed neuronal direction we have shown in the current
study decreases the likelihood of arresting future investi-leagues (37) examined transplanted hNP generated by
PA6 stromal coculture up to 3 weeks posttransplanta- gations due to hyperplasic hNPs, as has recently been
required in some studies (1). The assessment of sponta-tion. They reported mainly immature (nestin and TUJ1
positive) neuronal differentiation of PA6-generated hNP neously derived or noggin-primed hNPs on sensorimotor
function was not included in this current study due tofollowing transplantation into the QA-lesioned striatum.
This is in contrast to the current study where the major- the small group sizes. However, additional long-term
studies elucidating the functional effects of noggin-ity of transplanted hNP were highly neuronally directed,
and even at 4 weeks expressed mature neuronal markers, primed hNP on a variety of sensorimotor deficits pro-
duced by QA striatal lesioning, and the ability for trans-such as MAP2 or NeuN. While Song and colleagues
(37) did not report the presence of hyperplasia, the study planted hNP to form appropriately integrated mature
medium spiny striatal neurons, will be necessary to con-did not investigate hNP cell fate beyond 3 weeks post-
transplant, which may have misrepresented the potential firm and further establish the therapeutic potential of
hESC-derived hNP transplantation for HD. The QA le-safety of their PA6-generated hNP. In the current study
the overgrowth and appearance of rosette-like forma- sion model was used in this initial study to provide a
rapid, reliable, and well-substantiated model of the se-tions was not apparent until 8 weeks posttransplantation
and was only observed in grafts of spontaneously de- lective and extensive striatal cell loss observed in HD.
Transgenic mouse models of HD are more predictive torived hNP. Disparities between these studies may reflect
differences in cell fate determined by noggin priming of the clinical situation, and future studies using transgenic
models of HD are also necessary in order to assesshNP versus PA6 stromal coculture methods, and the
extent of differentiation that will be induced by longer whether the diseased host brain affects the long-term ef-
ficiency of hESC-derived hNP transplants.periods that the graft is in vivo (3 vs. 4 and 8 weeks
posttransplant). In support of this later point, a recent
ACKNOWLEDGMENTS: This work was supported by theinvestigation (1) using MS5 stromal-induced hNP
Health Research Council of New Zealand, the Royal Societygrafted into the QA-lesioned striatum found that it was
of New Zealand, and the University of Auckland Staff Re-
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